TGen, Mayo ‘liquid biopsy’ a game changer for earlier cancer detection
A new type of blood test for breast cancer – a “liquid biopsy” – could be a game-changer for earlier…
Read MoreBioscience Sponsor
Like what you’re seeing?
See more of our articles and other fresh Arizona Business content in our our digital versions of our AZ Business publication, and learn more about the magazine!
AZ Business PublicationAll Bioscience Articles
AZBio finalizes lineup for Arizona Bioscience Week
The Arizona Bioindustry Association (AZBio) today announced the final line up for the fourth annual Arizona Bioscience Week which will begin on…
Read MoreTGen and Ohio State collaborate on landmark canine cancer study
Despite those velvet paintings of poker-playing dogs smoking pipes, cigars and cigarettes, our canine friends really don’t use tobacco. But…
Read MoreTGen links gene to children with disabilities
Modern science and data sharing converged to underpin a study led by the Translational Genomics Research Institute (TGen), an affiliate…
Read MoreNew ‘liquid biopsy’ blood test improves breast cancer diagnostics
A new type of blood test for breast cancer could help avoid thousands of unnecessary surgeries and otherwise precisely monitor…
Read MoreTGen and ABL plan global rollout of advanced test for TB
Advanced Biological Laboratories (ABL) is expected to soon begin manufacturing of a compact, portable and affordable test for tuberculosis (TB),…
Read MoreBioLife Plasma Services brings jobs to Mesa, Phoenix and Tempe
BioLife Plasma Services is announcing the opening of a new plasma donation center in Tempe on Saturday, July 27. The…
Read MoreBioLife Plasma Services expands Arizona presence
BioLife Plasma Services annouced the opening of a new plasma donation center in Mesa on Saturday, June 22. The opening…
Read MoreHere’s how you can help TGen researchers understand Alzheimer’s disease
Did you know you can take a simple, 10-minute memory test to help researchers understand Alzheimer’s disease? MindCrowd, designed by…
Read MoreOncoMyx Therapeutics completes $25M Series A financing
OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company founded on the myxoma virus (MYXV) platform from Arizona State University (ASU), announced…
Read More
